Inventor
Chih-Chiang Tsou
Inventor
Pearland, TX, US
Overview
Patents· 54 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes20%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%
C07DHeterocyclic compounds20%
C07KPeptides20%
C12NMicroorganisms or enzymes20%
PatentTitleYear
11,103,535Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202111,077,142Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202111,065,279Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202111,058,727Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202111,052,114Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202111,052,113Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202111,040,069Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202111,033,585Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202111,033,583Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202111,026,977Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202111,020,434Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202111,020,433Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202111,013,768Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202111,013,769Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202111,013,766Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202110,993,962Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202110,993,964Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202110,905,719Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202110,905,720Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202110,898,518Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202110,898,519Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202110,894,064Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202110,888,585Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202110,888,586Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202110,888,584Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202110,888,583Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202110,888,582Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202110,874,696Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,874,695Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,869,893Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,869,892Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,869,891Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,869,894Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,869,890Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,869,895Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,869,896Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,813,953Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,799,537Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,792,308Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,792,307Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,780,123Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,780,124Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,780,122Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,772,915Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,751,369Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,709,736Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,709,737Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,709,738Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,702,553Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,695,377Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,695,373Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,695,374Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,695,376Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers202010,695,375Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers2020Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2020–2021Patents assigned to IMMATICS BIOTECHNOLOGIES GMBH (54)· patent assignee history
2020–2021Based in Pearland, TX, US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| IMMATICS BIOTECHNOLOGIES GMBH | 54 | 2020–2021 |
Locations
| Location | Patents | Span |
|---|---|---|
| Pearland, Texas, US | 54 | 2020–2021 |